Loading peptide directory…
Side-by-side
Pick up to 3 peptides and see their key facts side by side. Useful for narrowing a search before deciding which page to read in full.
1 of 3 selected.
| Field | Last updated |
|---|---|
| Aliases | Bremelanotide, Vyleesi, PT141, NDA 210557 |
| Category | Sexual Health |
| Formula | C₅₀H₆₈N₁₄O₁₀ |
| Molecular weight | 1025.18 Da |
| Half-life | ~2 hours |
| Mechanism (summary) | PT-141 (bremelanotide, brand name Vyleesi) is a nonselective melanocortin receptor agonist and the only peptide in this batch with a current FDA therapeutic label. It is approved for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. It acts centrally on melanocortin signaling — not as a vasodilator. |
| Dosing notes | Approved dose: 1.75 mg subcutaneously in abdomen or thigh, as needed, at least 45 minutes before sexual activity. Maximum 1 dose per 24 hours and no more than 8 doses per month. Contraindicated in uncontrolled hypertension or known cardiovascular disease. |
| Storage | Per FDA label: store at or below 25 °C, protect from light, do not freeze. |
|---|
| Read more | Full reference → |
|---|